Astellas Pharma Inc. (ALPMF)
OTCMKTS · Delayed Price · Currency is USD
10.46
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT
Astellas Pharma Employees
Astellas Pharma had 13,643 employees as of March 31, 2025. The number of employees decreased by 1,111 or -7.53% compared to the previous year.
Employees
13,643
Change (1Y)
-1,111
Growth (1Y)
-7.53%
Revenue / Employee
$988,130
Profits / Employee
$41,439
Market Cap
19.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13,643 | -1,111 | -7.53% |
| Mar 31, 2024 | 14,754 | 270 | 1.86% |
| Mar 31, 2023 | 14,484 | -38 | -0.26% |
| Mar 31, 2022 | 14,522 | -933 | -6.04% |
| Mar 31, 2021 | 15,455 | -428 | -2.69% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Astellas Pharma News
- 16 days ago - Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program" - PRNewsWire
- 17 days ago - China hands 3-1/2-year prison sentence to Astellas' Japanese employee, Nikkei says - Yahoo
- 17 days ago - China jails Japanese businessman for espionage, embassy says - Al Jazeera
- 17 days ago - Chinese court sentences a Japanese man to more than 3 years in prison on espionage charges - Yahoo
- 22 days ago - Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study - Benzinga
- 7 weeks ago - Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan - PRNewsWire
- 7 weeks ago - Lupin shares in focus after US Court rejects plea in Astellas Patent case - Business Upturn
- 2 months ago - Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - PRNewsWire